As outlined by ACR pointers, allopurinol is strongly suggested as a primary-line urate-reducing medication. Genetic screening is recommended (for a variant named HLA B*5801) ahead of beginning allopurinol since the carriers of this gene are at an elevated risk of the critical allergic response. D